Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
BACKGROUND The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States...
Uložené v:
| Vydané v: | Cancer Ročník 124; číslo 13; s. 2785 - 2800 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Wiley Subscription Services, Inc
01.07.2018
John Wiley and Sons Inc |
| Predmet: | |
| ISSN: | 0008-543X, 1097-0142, 1097-0142 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | BACKGROUND
The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States.
METHODS
Incidence data were obtained from the CDC‐funded and NCI‐funded population‐based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the National Center for Health Statistics National Vital Statistics System. Trends in age‐standardized incidence and death rates for all cancers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the annual percent change. Stage distribution and 5‐year survival by stage at diagnosis were calculated for breast cancer, colon and rectum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin.
RESULTS
Overall cancer incidence rates from 2008 to 2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015 decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5‐year period (2010‐2014) decreased for 7 of the 17 most common cancer types, and death rates (2011‐2015) decreased for 11 of the 18 most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14 of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal (men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other racial groups, and black men and black women had the highest death rates compared with other racial groups. Non‐Hispanic men and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five‐year survival for cases diagnosed from 2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV) for colorectal cancer, from 55.1% (stage I) to 4.2% (stage IV) for lung and bronchus cancer, and from 99.5% (stage I) to 16% (stage IV) for melanoma of the skin. Among children, overall cancer incidence rates increased by 0.8% per year from 2010 to 2014, and overall cancer death rates decreased by 1.5% per year from 2011 to 2015.
CONCLUSIONS
For all cancer sites combined, cancer incidence rates decreased among men but were stable among women. Overall, there continue to be significant declines in cancer death rates among both men and women. Differences in rates and trends by race and ethnic group remain. Progress in reducing cancer mortality has not occurred for all sites. Examining stage distribution and 5‐year survival by stage highlights the potential benefits associated with early detection and treatment. Cancer 2018;124:2785‐2800. © 2018 American Cancer Society
The National Cancer Institute, the Centers for Disease Control and Prevention, the American Cancer Society, and the North American Association of Central Cancer Registries collaborate annually to provide updated information about cancer occurrence and trends in the United States. Part I of this year's report highlights the continued declines in cancer incidence and mortality among men and in cancer mortality among women. It notes that differences in rates and trends by race and ethnic group remain, and progress in reducing cancer mortality has not occurred for all sites.See also pages 2801‐14. |
|---|---|
| AbstractList | BACKGROUND
The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States.
METHODS
Incidence data were obtained from the CDC‐funded and NCI‐funded population‐based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the National Center for Health Statistics National Vital Statistics System. Trends in age‐standardized incidence and death rates for all cancers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the annual percent change. Stage distribution and 5‐year survival by stage at diagnosis were calculated for breast cancer, colon and rectum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin.
RESULTS
Overall cancer incidence rates from 2008 to 2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015 decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5‐year period (2010‐2014) decreased for 7 of the 17 most common cancer types, and death rates (2011‐2015) decreased for 11 of the 18 most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14 of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal (men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other racial groups, and black men and black women had the highest death rates compared with other racial groups. Non‐Hispanic men and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five‐year survival for cases diagnosed from 2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV) for colorectal cancer, from 55.1% (stage I) to 4.2% (stage IV) for lung and bronchus cancer, and from 99.5% (stage I) to 16% (stage IV) for melanoma of the skin. Among children, overall cancer incidence rates increased by 0.8% per year from 2010 to 2014, and overall cancer death rates decreased by 1.5% per year from 2011 to 2015.
CONCLUSIONS
For all cancer sites combined, cancer incidence rates decreased among men but were stable among women. Overall, there continue to be significant declines in cancer death rates among both men and women. Differences in rates and trends by race and ethnic group remain. Progress in reducing cancer mortality has not occurred for all sites. Examining stage distribution and 5‐year survival by stage highlights the potential benefits associated with early detection and treatment. Cancer 2018;124:2785‐2800. © 2018 American Cancer Society
The National Cancer Institute, the Centers for Disease Control and Prevention, the American Cancer Society, and the North American Association of Central Cancer Registries collaborate annually to provide updated information about cancer occurrence and trends in the United States. Part I of this year's report highlights the continued declines in cancer incidence and mortality among men and in cancer mortality among women. It notes that differences in rates and trends by race and ethnic group remain, and progress in reducing cancer mortality has not occurred for all sites.See also pages 2801‐14. BACKGROUNDThe American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States.METHODSIncidence data were obtained from the CDC‐funded and NCI‐funded population‐based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the National Center for Health Statistics National Vital Statistics System. Trends in age‐standardized incidence and death rates for all cancers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the annual percent change. Stage distribution and 5‐year survival by stage at diagnosis were calculated for breast cancer, colon and rectum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin.RESULTSOverall cancer incidence rates from 2008 to 2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015 decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5‐year period (2010‐2014) decreased for 7 of the 17 most common cancer types, and death rates (2011‐2015) decreased for 11 of the 18 most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14 of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal (men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other racial groups, and black men and black women had the highest death rates compared with other racial groups. Non‐Hispanic men and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five‐year survival for cases diagnosed from 2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV) for colorectal cancer, from 55.1% (stage I) to 4.2% (stage IV) for lung and bronchus cancer, and from 99.5% (stage I) to 16% (stage IV) for melanoma of the skin. Among children, overall cancer incidence rates increased by 0.8% per year from 2010 to 2014, and overall cancer death rates decreased by 1.5% per year from 2011 to 2015.CONCLUSIONSFor all cancer sites combined, cancer incidence rates decreased among men but were stable among women. Overall, there continue to be significant declines in cancer death rates among both men and women. Differences in rates and trends by race and ethnic group remain. Progress in reducing cancer mortality has not occurred for all sites. Examining stage distribution and 5‐year survival by stage highlights the potential benefits associated with early detection and treatment. Cancer 2018;124:2785‐2800. © 2018 American Cancer Society The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States. Incidence data were obtained from the CDC-funded and NCI-funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the National Center for Health Statistics National Vital Statistics System. Trends in age-standardized incidence and death rates for all cancers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the annual percent change. Stage distribution and 5-year survival by stage at diagnosis were calculated for breast cancer, colon and rectum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin. Overall cancer incidence rates from 2008 to 2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015 decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5-year period (2010-2014) decreased for 7 of the 17 most common cancer types, and death rates (2011-2015) decreased for 11 of the 18 most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14 of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal (men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other racial groups, and black men and black women had the highest death rates compared with other racial groups. Non-Hispanic men and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five-year survival for cases diagnosed from 2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV) for colorectal cancer, from 55.1% (stage I) to 4.2% (stage IV) for lung and bronchus cancer, and from 99.5% (stage I) to 16% (stage IV) for melanoma of the skin. Among children, overall cancer incidence rates increased by 0.8% per year from 2010 to 2014, and overall cancer death rates decreased by 1.5% per year from 2011 to 2015. For all cancer sites combined, cancer incidence rates decreased among men but were stable among women. Overall, there continue to be significant declines in cancer death rates among both men and women. Differences in rates and trends by race and ethnic group remain. Progress in reducing cancer mortality has not occurred for all sites. Examining stage distribution and 5-year survival by stage highlights the potential benefits associated with early detection and treatment. Cancer 2018;124:2785-2800. © 2018 American Cancer Society. The National Cancer Institute, the Centers for Disease Control and Prevention, the American Cancer Society, and the North American Association of Central Cancer Registries collaborate annually to provide updated information about cancer occurrence and trends in the United States. Part I of this year's report highlights the continued declines in cancer incidence and mortality among men and in cancer mortality among women. It notes that differences in rates and trends by race and ethnic group remain, and progress in reducing cancer mortality has not occurred for all sites.See also pages 2801‐14. The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States.BACKGROUNDThe American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States.Incidence data were obtained from the CDC-funded and NCI-funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the National Center for Health Statistics National Vital Statistics System. Trends in age-standardized incidence and death rates for all cancers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the annual percent change. Stage distribution and 5-year survival by stage at diagnosis were calculated for breast cancer, colon and rectum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin.METHODSIncidence data were obtained from the CDC-funded and NCI-funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the National Center for Health Statistics National Vital Statistics System. Trends in age-standardized incidence and death rates for all cancers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the annual percent change. Stage distribution and 5-year survival by stage at diagnosis were calculated for breast cancer, colon and rectum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin.Overall cancer incidence rates from 2008 to 2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015 decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5-year period (2010-2014) decreased for 7 of the 17 most common cancer types, and death rates (2011-2015) decreased for 11 of the 18 most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14 of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal (men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other racial groups, and black men and black women had the highest death rates compared with other racial groups. Non-Hispanic men and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five-year survival for cases diagnosed from 2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV) for colorectal cancer, from 55.1% (stage I) to 4.2% (stage IV) for lung and bronchus cancer, and from 99.5% (stage I) to 16% (stage IV) for melanoma of the skin. Among children, overall cancer incidence rates increased by 0.8% per year from 2010 to 2014, and overall cancer death rates decreased by 1.5% per year from 2011 to 2015.RESULTSOverall cancer incidence rates from 2008 to 2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015 decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5-year period (2010-2014) decreased for 7 of the 17 most common cancer types, and death rates (2011-2015) decreased for 11 of the 18 most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14 of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal (men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other racial groups, and black men and black women had the highest death rates compared with other racial groups. Non-Hispanic men and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five-year survival for cases diagnosed from 2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV) for colorectal cancer, from 55.1% (stage I) to 4.2% (stage IV) for lung and bronchus cancer, and from 99.5% (stage I) to 16% (stage IV) for melanoma of the skin. Among children, overall cancer incidence rates increased by 0.8% per year from 2010 to 2014, and overall cancer death rates decreased by 1.5% per year from 2011 to 2015.For all cancer sites combined, cancer incidence rates decreased among men but were stable among women. Overall, there continue to be significant declines in cancer death rates among both men and women. Differences in rates and trends by race and ethnic group remain. Progress in reducing cancer mortality has not occurred for all sites. Examining stage distribution and 5-year survival by stage highlights the potential benefits associated with early detection and treatment. Cancer 2018;124:2785-2800. © 2018 American Cancer Society.CONCLUSIONSFor all cancer sites combined, cancer incidence rates decreased among men but were stable among women. Overall, there continue to be significant declines in cancer death rates among both men and women. Differences in rates and trends by race and ethnic group remain. Progress in reducing cancer mortality has not occurred for all sites. Examining stage distribution and 5-year survival by stage highlights the potential benefits associated with early detection and treatment. Cancer 2018;124:2785-2800. © 2018 American Cancer Society. |
| Author | Firth, Albert U. Jemal, Ahmedin Kohler, Betsy A. Howlader, Nadia Lake, Andrew J. Henley, S. Jane Scott, Susan Ma, Jiemin Sherman, Recinda L. Anderson, Robert N. Cronin, Kathleen A. Noone, Anne‐Michelle |
| AuthorAffiliation | 2 Information Management Services, Inc. Rockville Maryland 3 North American Association of Central Cancer Registries Springfield Illinois 1 Division of Cancer Control and Population Sciences National Cancer Institute Bethesda Maryland 4 Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention Atlanta Georgia 6 Surveillance and Health Services Research American Cancer Society Atlanta Georgia 5 National Center for Health Statistics, Centers for Disease Control and Prevention Hyattsville Maryland |
| AuthorAffiliation_xml | – name: 6 Surveillance and Health Services Research American Cancer Society Atlanta Georgia – name: 3 North American Association of Central Cancer Registries Springfield Illinois – name: 4 Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention Atlanta Georgia – name: 5 National Center for Health Statistics, Centers for Disease Control and Prevention Hyattsville Maryland – name: 1 Division of Cancer Control and Population Sciences National Cancer Institute Bethesda Maryland – name: 2 Information Management Services, Inc. Rockville Maryland |
| Author_xml | – sequence: 1 givenname: Kathleen A. surname: Cronin fullname: Cronin, Kathleen A. email: cronink@mail.nih.gov organization: National Cancer Institute – sequence: 2 givenname: Andrew J. surname: Lake fullname: Lake, Andrew J. organization: Information Management Services, Inc – sequence: 3 givenname: Susan orcidid: 0000-0001-5881-8313 surname: Scott fullname: Scott, Susan organization: National Cancer Institute – sequence: 4 givenname: Recinda L. surname: Sherman fullname: Sherman, Recinda L. organization: North American Association of Central Cancer Registries – sequence: 5 givenname: Anne‐Michelle surname: Noone fullname: Noone, Anne‐Michelle organization: National Cancer Institute – sequence: 6 givenname: Nadia surname: Howlader fullname: Howlader, Nadia organization: National Cancer Institute – sequence: 7 givenname: S. Jane surname: Henley fullname: Henley, S. Jane organization: Centers for Disease Control and Prevention – sequence: 8 givenname: Robert N. surname: Anderson fullname: Anderson, Robert N. organization: National Center for Health Statistics, Centers for Disease Control and Prevention – sequence: 9 givenname: Albert U. surname: Firth fullname: Firth, Albert U. organization: Information Management Services, Inc – sequence: 10 givenname: Jiemin surname: Ma fullname: Ma, Jiemin organization: American Cancer Society – sequence: 11 givenname: Betsy A. surname: Kohler fullname: Kohler, Betsy A. organization: North American Association of Central Cancer Registries – sequence: 12 givenname: Ahmedin orcidid: 0000-0002-0000-4111 surname: Jemal fullname: Jemal, Ahmedin organization: American Cancer Society |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29786848$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kV1rFDEUhoO02G31xh8gAW-KOPXkaybrRaEMagulQlX0LqTZxKbMJmuSUfrvzexuSy0ihBMO53lfzsc-2gkxWIReEDgiAPStCSYdMSIEeYJmBOZdA4TTHTQDANkIzr7vof2cb2raUcGeoj0672QruZyhbychjHrAl3YVU8El4nJt8YUuPgZc35R9LrqMGUeHex2MTW_wSlf27N2Wq3KzLuBcSZ-LN_kZ2nV6yPb59j9AXz-8_9KfNuefPp71J-eNEYSTRhJumIY5s1fMtc4a6fgUOsJabR1baJBULIATSV1NOOEMHJHG1GmhW7ADdLzxXY1XS7swNpSkB7VKfqnTrYraq78rwV-rH_GXaoExIttqcLg1SPHnaHNRS5-NHQYdbByzosBpJ4iQpKKvHqE3cUx1_IkSLWeMAa3Uy4cd3bdyt_MKvN4AJsWck3X3CAE1HVRNB1Xrg1YYHsHGl_XW6zR--LeEbCS__WBv_2Ou-ov-cqP5A-z2shU |
| CitedBy_id | crossref_primary_10_3389_fcell_2020_582695 crossref_primary_10_1186_s12957_020_02018_z crossref_primary_10_1097_PR9_0000000000000867 crossref_primary_10_1177_1073274820906811 crossref_primary_10_3390_pharmaceutics14102051 crossref_primary_10_1161_JAHA_119_015306 crossref_primary_10_1002_cbin_11215 crossref_primary_10_1002_jso_27697 crossref_primary_10_1080_08998280_2024_2346404 crossref_primary_10_1016_j_bbrc_2023_06_082 crossref_primary_10_1016_j_prp_2018_10_037 crossref_primary_10_1016_j_cct_2025_108051 crossref_primary_10_1016_j_critrevonc_2020_103187 crossref_primary_10_1186_s12967_023_04153_z crossref_primary_10_1016_j_suronc_2024_102114 crossref_primary_10_3390_metabo10080317 crossref_primary_10_1007_s00520_019_05150_z crossref_primary_10_1016_j_jpainsymman_2020_01_014 crossref_primary_10_1038_s41598_022_15351_y crossref_primary_10_1016_j_amepre_2021_07_019 crossref_primary_10_3389_fonc_2021_690390 crossref_primary_10_3389_fonc_2022_914192 crossref_primary_10_1016_j_ypmed_2019_105928 crossref_primary_10_1259_dmfr_20180416 crossref_primary_10_2174_1381612829666230426115424 crossref_primary_10_1177_000313482008600423 crossref_primary_10_3390_cancers12113090 crossref_primary_10_3892_etm_2020_8726 crossref_primary_10_1111_cpr_13578 crossref_primary_10_1007_s11095_021_03139_0 crossref_primary_10_1097_RCT_0000000000001025 crossref_primary_10_1016_j_techsoc_2021_101762 crossref_primary_10_1177_00034894211007219 crossref_primary_10_1016_j_ijrobp_2023_11_040 crossref_primary_10_1016_j_molstruc_2019_05_014 crossref_primary_10_1093_humupd_dmz027 crossref_primary_10_1002_advs_202002178 crossref_primary_10_1016_j_preteyeres_2018_09_003 crossref_primary_10_1146_annurev_cancerbio_030419_033502 crossref_primary_10_1186_s13104_018_3504_5 crossref_primary_10_1002_cncr_32365 crossref_primary_10_1002_wjo2_15 crossref_primary_10_1093_nar_gkaa661 crossref_primary_10_1038_s41574_019_0221_7 crossref_primary_10_1016_j_ctro_2019_09_002 crossref_primary_10_1016_j_patol_2019_12_001 crossref_primary_10_1186_s12885_021_08692_w crossref_primary_10_1007_s10552_020_01285_1 crossref_primary_10_1053_j_sult_2019_05_002 crossref_primary_10_3390_cells8080803 crossref_primary_10_1111_nhs_12677 crossref_primary_10_1016_j_zemedi_2024_07_004 crossref_primary_10_3389_fimmu_2020_00508 crossref_primary_10_3390_biom10060934 crossref_primary_10_1007_s11938_020_00271_5 crossref_primary_10_1371_journal_pone_0236402 crossref_primary_10_32604_biocell_2022_016962 crossref_primary_10_3390_cancers17142338 crossref_primary_10_1016_j_mcna_2020_08_005 crossref_primary_10_1038_s41598_019_55613_w crossref_primary_10_1053_j_sult_2021_04_015 crossref_primary_10_1016_j_clinimag_2021_11_008 crossref_primary_10_1038_s41419_020_02959_z crossref_primary_10_1186_s12885_021_08012_2 crossref_primary_10_1016_j_oret_2020_09_007 crossref_primary_10_1093_jncics_pkac017 crossref_primary_10_1016_j_canep_2020_101762 crossref_primary_10_1016_j_ejmp_2019_05_022 crossref_primary_10_1097_SGA_0000000000000664 crossref_primary_10_9778_cmajo_20210219 crossref_primary_10_1002_pbc_29437 crossref_primary_10_3892_ol_2019_10362 crossref_primary_10_1016_j_ypmed_2019_105824 crossref_primary_10_1016_j_ygyno_2021_03_008 crossref_primary_10_1200_EDBK_238965 crossref_primary_10_1002_jso_26278 crossref_primary_10_1089_jchc_19_09_0073 crossref_primary_10_3389_fonc_2021_746058 crossref_primary_10_1007_s11888_019_00432_4 crossref_primary_10_1002_ajim_22955 crossref_primary_10_1002_pd_5379 crossref_primary_10_1007_s00383_018_4388_0 crossref_primary_10_2967_jnmt_122_264714 crossref_primary_10_1016_j_clindermatol_2024_09_008 crossref_primary_10_1016_j_jddst_2021_102782 crossref_primary_10_32628_IJSRST207347 crossref_primary_10_1186_s12935_019_0909_8 crossref_primary_10_3389_fphar_2023_1138742 crossref_primary_10_1111_1759_7714_13644 crossref_primary_10_1097_MD_0000000000018082 crossref_primary_10_1186_s12943_022_01680_z crossref_primary_10_1111_ajco_13582 crossref_primary_10_1016_j_ejrad_2021_109745 crossref_primary_10_1186_s12951_021_00874_9 crossref_primary_10_1002_lio2_370 crossref_primary_10_1177_2042018820943377 crossref_primary_10_1080_07391102_2023_2214233 crossref_primary_10_1007_s12282_021_01245_w crossref_primary_10_1016_j_envpol_2024_124975 crossref_primary_10_1007_s11938_020_00274_2 crossref_primary_10_3390_cancers17061035 crossref_primary_10_4132_jptm_2019_10_01 crossref_primary_10_3390_healthcare8020172 crossref_primary_10_1155_2020_5701527 crossref_primary_10_3390_molecules25030652 crossref_primary_10_1186_s12645_023_00228_0 crossref_primary_10_1016_j_actbio_2024_04_037 crossref_primary_10_1016_j_jlumin_2020_117627 crossref_primary_10_1158_0008_5472_CAN_19_2270 crossref_primary_10_1186_s12943_024_02201_w crossref_primary_10_1016_j_jtho_2021_07_007 crossref_primary_10_1007_s11042_022_12017_9 crossref_primary_10_3389_fendo_2019_00547 crossref_primary_10_3322_caac_21494 crossref_primary_10_1053_j_jvca_2021_11_014 crossref_primary_10_1016_j_neo_2019_07_010 crossref_primary_10_1186_s13048_021_00896_9 crossref_primary_10_3390_biom12030464 crossref_primary_10_1007_s11864_019_0676_8 crossref_primary_10_1080_13697137_2019_1606795 crossref_primary_10_1089_jwh_2019_7752 crossref_primary_10_1016_j_athoracsur_2020_07_048 crossref_primary_10_1007_s00520_019_05186_1 crossref_primary_10_3389_fpubh_2022_1060798 crossref_primary_10_2217_bmm_2019_0228 crossref_primary_10_1016_j_lfs_2019_117060 crossref_primary_10_1053_j_gastro_2019_07_040 crossref_primary_10_1002_aoc_6235 crossref_primary_10_3390_diagnostics11040684 crossref_primary_10_1016_j_jinorgbio_2020_111063 crossref_primary_10_1089_jpm_2018_0528 crossref_primary_10_1093_neuonc_noy189 crossref_primary_10_1007_s00262_023_03469_5 crossref_primary_10_1016_S0007_4551_20_30041_2 crossref_primary_10_1007_s00261_022_03526_0 crossref_primary_10_1007_s00520_022_07061_y crossref_primary_10_1038_s41556_019_0407_1 crossref_primary_10_1016_j_jgo_2022_10_008 crossref_primary_10_3892_ijo_2020_5111 crossref_primary_10_1016_j_ejogrb_2021_11_016 crossref_primary_10_1097_PHH_0000000000001144 crossref_primary_10_1007_s11912_021_01129_4 crossref_primary_10_3390_ijms22094394 crossref_primary_10_3390_cancers11060806 crossref_primary_10_4251_wjgo_v13_i11_1766 crossref_primary_10_1080_13543776_2019_1623880 crossref_primary_10_1158_1078_0432_CCR_20_0418 crossref_primary_10_1177_10901981211001851 crossref_primary_10_1016_j_bulcan_2022_05_003 crossref_primary_10_3390_ijms21186757 crossref_primary_10_1016_j_athoracsur_2020_09_088 crossref_primary_10_1016_j_pec_2021_07_033 crossref_primary_10_1177_00099228231191957 crossref_primary_10_1007_s12029_019_00287_w crossref_primary_10_3389_fonc_2023_1067849 crossref_primary_10_1016_j_jogc_2023_102278 crossref_primary_10_2147_CMAR_S270200 crossref_primary_10_1001_jamanetworkopen_2022_40657 crossref_primary_10_1007_s11888_018_0420_y crossref_primary_10_1016_j_bioelechem_2021_107744 crossref_primary_10_1007_s00432_020_03309_4 crossref_primary_10_1186_s12903_022_02157_7 crossref_primary_10_1093_jnci_djad002 crossref_primary_10_1177_0300060521991019 crossref_primary_10_1111_pcmr_12817 crossref_primary_10_4103_jispcd_jispcd_42_25 crossref_primary_10_1007_s13187_021_02067_2 crossref_primary_10_1016_j_pmedr_2025_103180 crossref_primary_10_1161_JAHA_119_014248 crossref_primary_10_1097_MD_0000000000021688 crossref_primary_10_3390_cancers14092146 crossref_primary_10_1016_j_breast_2025_104502 crossref_primary_10_1200_JCO_18_02037 crossref_primary_10_1002_cam4_2092 crossref_primary_10_1007_s00404_020_05798_7 crossref_primary_10_3390_medicina57010024 crossref_primary_10_1158_1940_6207_CAPR_20_0524 crossref_primary_10_1016_j_biocel_2019_105643 crossref_primary_10_1016_j_respe_2021_01_004 crossref_primary_10_3389_fcell_2021_682060 crossref_primary_10_3389_fbioe_2024_1424553 crossref_primary_10_1177_0030222819852836 crossref_primary_10_1155_2022_7326537 crossref_primary_10_1016_j_xfre_2023_11_005 crossref_primary_10_1080_21691401_2019_1629952 crossref_primary_10_3390_cancers11010048 crossref_primary_10_1002_cam4_3471 crossref_primary_10_1038_s41467_022_29684_9 crossref_primary_10_1186_s40463_022_00564_y crossref_primary_10_1007_s10620_021_07276_9 crossref_primary_10_1097_SGA_0000000000000807 crossref_primary_10_1002_ijc_32871 crossref_primary_10_1016_j_hjdsi_2021_100565 crossref_primary_10_3390_ph14121325 crossref_primary_10_1093_jbi_wbad054 crossref_primary_10_1007_s10238_022_00873_6 crossref_primary_10_1016_j_molimm_2021_01_010 crossref_primary_10_1158_1078_0432_CCR_19_2896 crossref_primary_10_1016_j_ccm_2019_10_001 crossref_primary_10_1016_j_ygeno_2021_08_024 crossref_primary_10_1093_tbm_ibab081 crossref_primary_10_14309_ajg_0000000000000546 crossref_primary_10_1016_j_ypmed_2019_105763 crossref_primary_10_1002_gcc_22993 crossref_primary_10_1007_s10552_019_01244_5 crossref_primary_10_3892_ol_2022_13553 crossref_primary_10_1371_journal_pone_0232577 crossref_primary_10_1002_cbin_11196 crossref_primary_10_1007_s00120_020_01123_x crossref_primary_10_1038_s41698_025_00960_3 crossref_primary_10_1136_bmjspcare_2019_002097 crossref_primary_10_1371_journal_pone_0314655 crossref_primary_10_1097_MNM_0000000000001095 crossref_primary_10_1016_j_ygyno_2023_04_018 crossref_primary_10_1097_MD_0000000000028814 crossref_primary_10_1186_s12935_024_03267_8 crossref_primary_10_1186_s12935_020_01495_2 crossref_primary_10_1093_biomtc_ujad006 crossref_primary_10_3390_cancers13071729 crossref_primary_10_1001_jamanetworkopen_2021_44713 crossref_primary_10_1007_s11605_023_05868_6 crossref_primary_10_1038_s41698_020_0122_1 crossref_primary_10_1111_liv_14409 crossref_primary_10_1016_j_gtc_2022_05_002 crossref_primary_10_1007_s12094_019_02211_x crossref_primary_10_1016_j_cmpb_2023_107769 crossref_primary_10_3322_caac_21564 crossref_primary_10_1097_EDE_0000000000001394 crossref_primary_10_3390_cancers13071721 crossref_primary_10_1136_ijgc_2020_001804 crossref_primary_10_1186_s12885_019_6287_8 crossref_primary_10_1097_CEJ_0000000000000598 crossref_primary_10_1007_s10620_019_05913_y crossref_primary_10_3389_fonc_2021_705797 crossref_primary_10_3390_molecules23061471 crossref_primary_10_1038_s41392_024_01889_y crossref_primary_10_1016_j_ygyno_2021_04_028 crossref_primary_10_1016_j_cellsig_2024_111383 crossref_primary_10_1080_03007995_2019_1662688 crossref_primary_10_1002_cam4_70352 crossref_primary_10_1002_cncr_33049 crossref_primary_10_1016_j_jpha_2024_02_001 crossref_primary_10_3390_cancers12071797 crossref_primary_10_1080_00365521_2021_1974933 crossref_primary_10_3390_cancers13174407 crossref_primary_10_1097_TXD_0000000000001060 crossref_primary_10_1080_21655979_2021_1962694 crossref_primary_10_3322_caac_21551 crossref_primary_10_1016_j_suc_2019_02_002 crossref_primary_10_3390_jcm8060891 crossref_primary_10_1016_j_ijrobp_2020_03_016 crossref_primary_10_1111_aogs_14015 crossref_primary_10_7759_cureus_10083 crossref_primary_10_1080_10715762_2019_1593402 crossref_primary_10_1053_j_gastro_2019_02_046 crossref_primary_10_1016_j_bios_2019_01_062 crossref_primary_10_1093_jb_mvac013 crossref_primary_10_1177_1078155219900944 crossref_primary_10_1016_j_clbc_2018_11_007 crossref_primary_10_1038_s41571_020_0378_y crossref_primary_10_1007_s00066_020_01728_3 crossref_primary_10_1016_j_lfs_2021_119759 crossref_primary_10_3390_jcm9092682 crossref_primary_10_15585_mmwr_mm6748a1 crossref_primary_10_3390_ijms19061791 crossref_primary_10_1016_j_biomaterials_2019_119618 crossref_primary_10_3390_cancers16010050 crossref_primary_10_1097_PGP_0000000000000767 crossref_primary_10_1186_s12876_023_02974_2 crossref_primary_10_1007_s13187_019_01650_y crossref_primary_10_1016_j_ejps_2019_105106 crossref_primary_10_3322_caac_21548 crossref_primary_10_1007_s10552_021_01539_6 crossref_primary_10_1080_14712598_2019_1680636 crossref_primary_10_3389_fonc_2020_00699 crossref_primary_10_1002_14651858_CD015530_pub2 crossref_primary_10_1002_jbt_22403 crossref_primary_10_1007_s00384_021_04022_5 crossref_primary_10_1016_j_cmpb_2020_105606 crossref_primary_10_1155_2022_2687455 crossref_primary_10_3390_cancers16112052 crossref_primary_10_1016_j_radonc_2018_09_003 crossref_primary_10_1002_cbin_11139 crossref_primary_10_1016_j_lfs_2021_119431 crossref_primary_10_1097_PAP_0000000000000256 crossref_primary_10_3389_fgene_2021_730442 crossref_primary_10_1210_clinem_dgab195 crossref_primary_10_3390_cancers14071752 crossref_primary_10_1007_s40258_020_00626_0 crossref_primary_10_1186_s13063_021_05064_4 crossref_primary_10_2196_70510 crossref_primary_10_5812_jjcdc_99315 crossref_primary_10_1016_j_cgh_2018_12_041 crossref_primary_10_1016_j_ajpath_2019_02_009 crossref_primary_10_1111_ajes_12507 crossref_primary_10_3389_fonc_2020_00442 crossref_primary_10_1002_jso_25913 crossref_primary_10_3390_ijms232012168 crossref_primary_10_3390_nu11030519 crossref_primary_10_1007_s10653_022_01261_5 crossref_primary_10_1186_s43058_021_00221_x crossref_primary_10_1002_jcp_29086 crossref_primary_10_1038_s41523_022_00412_2 crossref_primary_10_3389_fgene_2019_00235 crossref_primary_10_1016_j_ypmed_2019_105849 crossref_primary_10_3390_ijms19082332 crossref_primary_10_1038_s41598_023_33537_w crossref_primary_10_1186_s13048_018_0467_z crossref_primary_10_2196_53058 crossref_primary_10_3390_cancers14163998 crossref_primary_10_1016_j_eururo_2020_07_018 crossref_primary_10_14309_ctg_0000000000000173 crossref_primary_10_1111_bjh_19373 crossref_primary_10_1159_000502714 crossref_primary_10_1245_s10434_021_10174_z crossref_primary_10_1016_j_jcpo_2021_100307 crossref_primary_10_3389_ijph_2022_1604988 crossref_primary_10_1136_neurintsurg_2020_016144 crossref_primary_10_1513_AnnalsATS_201907_556CME crossref_primary_10_1177_1010428320925237 crossref_primary_10_1016_j_clcc_2020_05_010 crossref_primary_10_1016_j_euf_2020_05_003 crossref_primary_10_1007_s11547_023_01644_3 crossref_primary_10_3389_fonc_2020_01766 crossref_primary_10_1016_j_bios_2018_09_062 crossref_primary_10_1155_2023_1702125 crossref_primary_10_1097_MOT_0000000000000695 crossref_primary_10_5435_JAAOS_D_18_00777 crossref_primary_10_1038_s41388_020_01397_7 crossref_primary_10_1016_j_cmet_2019_11_012 crossref_primary_10_1016_j_cles_2022_100009 crossref_primary_10_2196_43592 crossref_primary_10_3390_pharmaceutics14122795 crossref_primary_10_3389_fgene_2022_900380 crossref_primary_10_1016_S1470_2045_19_30687_4 crossref_primary_10_1177_1756284820917527 crossref_primary_10_1016_j_soncn_2019_06_002 crossref_primary_10_1053_j_gastro_2020_02_036 crossref_primary_10_1097_QAI_0000000000002024 crossref_primary_10_1016_j_bios_2019_02_070 crossref_primary_10_1016_j_radi_2024_03_015 crossref_primary_10_1007_s11060_020_03619_0 crossref_primary_10_1097_MOH_0000000000000572 crossref_primary_10_1016_j_semcancer_2021_03_028 crossref_primary_10_19127_bshealthscience_1363118 crossref_primary_10_1186_s12885_024_11819_4 crossref_primary_10_4081_reumatismo_2024_1632 crossref_primary_10_1002_hed_26172 crossref_primary_10_1016_j_chest_2021_05_026 crossref_primary_10_1038_s41391_019_0184_8 crossref_primary_10_1016_j_lungcan_2022_10_011 crossref_primary_10_1016_j_soncn_2019_06_013 crossref_primary_10_3390_cancers12061604 crossref_primary_10_1002_cncr_34047 crossref_primary_10_1111_1759_7714_13204 crossref_primary_10_1016_j_ejmech_2018_11_046 crossref_primary_10_3389_fonc_2022_1000993 crossref_primary_10_1155_2020_2046947 crossref_primary_10_1002_cam4_4608 crossref_primary_10_3389_fonc_2022_1043670 crossref_primary_10_1080_13685538_2019_1645109 crossref_primary_10_1002_cam4_3877 crossref_primary_10_1128_MCB_00307_19 crossref_primary_10_1007_s13346_021_00915_8 crossref_primary_10_1002_cam4_2663 crossref_primary_10_1002_jbt_23497 crossref_primary_10_1007_s10552_021_01451_z crossref_primary_10_7759_cureus_90288 crossref_primary_10_1007_s10812_022_01442_1 crossref_primary_10_1007_s00432_021_03802_4 crossref_primary_10_1177_0969141320921893 crossref_primary_10_1016_j_rbmo_2023_103767 crossref_primary_10_1002_pros_24076 crossref_primary_10_1186_s13019_024_02505_4 crossref_primary_10_2217_fon_2023_0412 crossref_primary_10_1007_s12668_024_01706_4 crossref_primary_10_3389_fsurg_2021_693387 crossref_primary_10_1186_s12880_024_01510_2 crossref_primary_10_3390_ph16030450 crossref_primary_10_1007_s11136_025_04031_9 crossref_primary_10_1080_07391102_2022_2060306 crossref_primary_10_1177_2050312120926877 crossref_primary_10_1088_2057_1976_ac3055 crossref_primary_10_3390_cancers12102750 crossref_primary_10_1093_ije_dyab275 crossref_primary_10_1177_10732748221121391 crossref_primary_10_1016_j_canlet_2019_12_002 crossref_primary_10_1016_j_ebiom_2019_11_022 crossref_primary_10_1007_s10815_021_02081_9 crossref_primary_10_1007_s13187_021_02060_9 crossref_primary_10_1016_j_gastha_2023_09_007 crossref_primary_10_1371_journal_pone_0284051 crossref_primary_10_31146_1682_8658_ecg_212_4_19_27 crossref_primary_10_1002_cncr_32802 crossref_primary_10_1007_s11307_019_01434_2 crossref_primary_10_1093_jnci_djz106 crossref_primary_10_3389_fcell_2020_575223 crossref_primary_10_1093_oncolo_oyac082 crossref_primary_10_1177_21501327211017792 crossref_primary_10_1016_j_biopha_2019_109604 crossref_primary_10_1002_cam4_2209 crossref_primary_10_1177_00031348241227165 crossref_primary_10_1016_j_lungcan_2019_11_015 crossref_primary_10_1016_j_isci_2023_107869 crossref_primary_10_1038_s41533_020_0173_3 crossref_primary_10_1002_mp_13458 crossref_primary_10_3389_fcell_2024_1516613 crossref_primary_10_1007_s10741_019_09808_y crossref_primary_10_1016_j_suronc_2019_12_004 crossref_primary_10_1038_s41419_020_03018_3 crossref_primary_10_1007_s11934_019_0932_2 crossref_primary_10_1097_CM9_0000000000001141 crossref_primary_10_1001_jamadermatol_2019_1134 crossref_primary_10_1016_j_nut_2023_112334 crossref_primary_10_1080_09637486_2019_1597025 crossref_primary_10_1245_s10434_022_12360_z crossref_primary_10_3389_fmed_2023_1130710 crossref_primary_10_1155_2022_9076175 crossref_primary_10_3322_caac_21714 crossref_primary_10_1038_s41598_020_69615_6 crossref_primary_10_1016_j_jep_2022_115285 crossref_primary_10_1111_cas_13838 crossref_primary_10_1016_j_radonc_2021_09_031 crossref_primary_10_3171_2019_2_SPINE181306 crossref_primary_10_1016_j_molstruc_2021_132228 crossref_primary_10_1111_den_13888 crossref_primary_10_3892_ol_2020_11827 crossref_primary_10_1016_j_neuron_2022_04_009 crossref_primary_10_1186_s43058_022_00285_3 crossref_primary_10_1155_2020_6107865 crossref_primary_10_1186_s12885_021_08796_3 crossref_primary_10_3389_fsurg_2022_843987 crossref_primary_10_1007_s12672_024_01595_9 crossref_primary_10_1002_emp2_12438 crossref_primary_10_1007_s40471_019_00192_7 crossref_primary_10_1007_s00277_019_03692_0 crossref_primary_10_1007_s13187_020_01922_y crossref_primary_10_1016_j_bbcan_2021_188621 crossref_primary_10_1007_s13126_019_0502_6 crossref_primary_10_1111_ecc_13079 crossref_primary_10_1016_j_wneu_2021_01_047 crossref_primary_10_1093_bib_bbaf134 crossref_primary_10_1016_j_omtn_2020_03_008 crossref_primary_10_1038_s41379_019_0340_7 crossref_primary_10_1097_PAI_0000000000000917 crossref_primary_10_1016_j_molstruc_2022_133826 crossref_primary_10_1080_21655979_2020_1868119 crossref_primary_10_3390_ijms19092543 crossref_primary_10_1038_s41598_021_97480_4 crossref_primary_10_1016_j_ctarc_2020_100295 crossref_primary_10_1177_1078155220959427 crossref_primary_10_3390_cancers15123135 crossref_primary_10_1186_s12885_022_09756_1 crossref_primary_10_1016_j_addr_2021_113896 crossref_primary_10_1016_j_bcp_2023_115773 crossref_primary_10_1007_s00268_021_06399_4 crossref_primary_10_1016_j_ejso_2020_11_007 crossref_primary_10_1080_02652048_2021_1902009 crossref_primary_10_1016_j_ygyno_2025_07_016 crossref_primary_10_3390_math10050829 crossref_primary_10_1089_cbr_2020_3800 crossref_primary_10_1016_j_ymthe_2019_04_005 crossref_primary_10_3389_fgene_2022_796681 crossref_primary_10_1016_j_ijrobp_2023_05_004 crossref_primary_10_1111_codi_16324 crossref_primary_10_7717_peerj_12315 crossref_primary_10_1002_hed_26475 crossref_primary_10_1016_j_ajog_2019_05_024 crossref_primary_10_1371_journal_pone_0230354 crossref_primary_10_1016_j_nano_2020_102213 crossref_primary_10_1111_hepr_13718 crossref_primary_10_1158_0008_5472_CAN_21_1747 crossref_primary_10_1016_j_thromres_2025_109259 crossref_primary_10_1053_j_gastro_2019_12_005 crossref_primary_10_1053_j_gastro_2019_12_002 crossref_primary_10_1002_pam_22199 crossref_primary_10_1007_s10549_020_05819_8 crossref_primary_10_3892_mmr_2019_10509 crossref_primary_10_1002_cam4_4706 crossref_primary_10_1177_0194599820951165 crossref_primary_10_1158_1078_0432_CCR_19_2685 crossref_primary_10_1002_cam4_3979 crossref_primary_10_1053_j_gastro_2019_02_012 crossref_primary_10_1002_adhm_201801221 crossref_primary_10_1016_j_prp_2023_154562 crossref_primary_10_3389_fonc_2021_746789 crossref_primary_10_3389_fonc_2022_830362 crossref_primary_10_3390_ph16070970 crossref_primary_10_1097_MD_0000000000017641 crossref_primary_10_3390_ijms22073801 crossref_primary_10_1186_s12967_020_02260_9 crossref_primary_10_1016_j_iliver_2023_03_001 crossref_primary_10_1007_s10989_020_10063_1 crossref_primary_10_1177_1073274820945991 crossref_primary_10_30621_jbachs_1056769 crossref_primary_10_1038_s41598_022_14644_6 crossref_primary_10_1097_MPA_0000000000001337 crossref_primary_10_1111_jdv_15285 crossref_primary_10_3892_mco_2018_1724 crossref_primary_10_3389_fcell_2020_566932 crossref_primary_10_1007_s10389_019_01069_1 crossref_primary_10_1016_j_acra_2018_06_025 crossref_primary_10_1067_j_cpradiol_2022_04_001 crossref_primary_10_1002_cam4_3861 crossref_primary_10_1136_jitc_2020_000810 crossref_primary_10_3389_fonc_2021_698888 crossref_primary_10_3389_fonc_2020_01461 crossref_primary_10_1002_cncr_32701 crossref_primary_10_1177_0003134820960081 crossref_primary_10_1111_odi_13640 crossref_primary_10_1016_j_jtcvs_2021_01_036 crossref_primary_10_1148_rg_2019180205 crossref_primary_10_1097_CORR_0000000000000523 crossref_primary_10_32604_biocell_2022_020325 crossref_primary_10_1155_2020_8846073 crossref_primary_10_1007_s10815_020_01935_y crossref_primary_10_3390_ijms21020569 crossref_primary_10_1016_j_ccm_2020_02_008 crossref_primary_10_1016_j_prp_2019_152466 crossref_primary_10_1007_s00262_024_03682_w crossref_primary_10_3389_fcell_2020_566494 crossref_primary_10_1002_sim_8458 crossref_primary_10_1097_AOG_0000000000005321 crossref_primary_10_3390_epigenomes2030015 crossref_primary_10_1523_ENEURO_0061_25_2025 crossref_primary_10_1111_cpr_12770 crossref_primary_10_1111_ajt_15181 crossref_primary_10_3390_cancers16071346 crossref_primary_10_3892_ol_2019_11060 crossref_primary_10_1016_j_radonc_2018_11_022 crossref_primary_10_3390_ijms25137306 crossref_primary_10_3389_fonc_2022_846568 crossref_primary_10_1093_ejcts_ezaa031 crossref_primary_10_3389_fgene_2021_633756 crossref_primary_10_1289_EHP7102 crossref_primary_10_21303_2504_5679_2020_001196 crossref_primary_10_1038_s41698_019_0097_y crossref_primary_10_1186_s12935_023_02849_2 crossref_primary_10_1016_j_canlet_2019_11_043 crossref_primary_10_1016_j_isci_2024_111572 crossref_primary_10_3389_fonc_2021_788875 crossref_primary_10_1186_s13046_020_01605_y crossref_primary_10_3389_fmed_2023_1205897 crossref_primary_10_3390_jpm13010033 crossref_primary_10_1016_j_tranon_2023_101842 crossref_primary_10_1016_j_molmed_2018_12_009 crossref_primary_10_3390_ijerph18157966 crossref_primary_10_1080_03602532_2019_1632886 crossref_primary_10_1093_pch_pxac123 crossref_primary_10_1155_2022_2055900 crossref_primary_10_1016_j_jgo_2020_05_010 crossref_primary_10_1039_D3NR05656B crossref_primary_10_1016_j_bbrc_2020_01_130 crossref_primary_10_1007_s10353_020_00672_x crossref_primary_10_1186_s12865_022_00502_7 crossref_primary_10_3390_cancers15061792 crossref_primary_10_1007_s00345_019_02719_5 crossref_primary_10_1016_j_oraloncology_2021_105547 crossref_primary_10_1007_s00066_019_01492_z crossref_primary_10_1016_j_urolonc_2021_04_026 crossref_primary_10_1080_03007995_2020_1824899 crossref_primary_10_3389_fmed_2019_00231 crossref_primary_10_1097_EDE_0000000000000981 crossref_primary_10_1002_cncr_31549 crossref_primary_10_1016_j_amjcard_2020_01_047 crossref_primary_10_3390_nu13041136 crossref_primary_10_1109_ACCESS_2024_3439397 crossref_primary_10_1007_s00415_019_09416_8 crossref_primary_10_1158_1541_7786_MCR_20_0881 crossref_primary_10_1016_j_celrep_2023_113295 crossref_primary_10_1007_s11606_020_06371_3 crossref_primary_10_1158_0008_5472_CAN_22_0682 crossref_primary_10_1002_cbdv_202300149 crossref_primary_10_1016_j_amepre_2019_03_015 crossref_primary_10_3389_fimmu_2023_1151800 crossref_primary_10_1111_ijun_12308 crossref_primary_10_1016_j_urolonc_2020_02_028 crossref_primary_10_1109_JBHI_2022_3151333 crossref_primary_10_1371_journal_pone_0263672 crossref_primary_10_1080_13557858_2020_1739231 crossref_primary_10_1002_prm2_12078 crossref_primary_10_1016_j_jid_2022_08_037 crossref_primary_10_1177_1078155220951612 crossref_primary_10_1016_j_ygyno_2020_06_481 crossref_primary_10_1007_s11701_020_01142_y crossref_primary_10_1002_jcb_29385 crossref_primary_10_1016_j_pop_2021_07_003 crossref_primary_10_1111_jgh_16618 crossref_primary_10_1155_2019_2584859 crossref_primary_10_1016_j_canlet_2021_08_039 crossref_primary_10_1016_j_ejro_2020_100264 crossref_primary_10_3390_cancers12113348 crossref_primary_10_1080_10717544_2019_1667454 crossref_primary_10_1002_jso_26314 crossref_primary_10_1111_pace_14196 crossref_primary_10_1016_j_cpsurg_2021_101030 crossref_primary_10_1158_1541_7786_MCR_20_0651 crossref_primary_10_1371_journal_pone_0260035 crossref_primary_10_1016_j_leukres_2019_106195 crossref_primary_10_3390_nu11081897 crossref_primary_10_5888_pcd19_210315 crossref_primary_10_1016_j_compbiomed_2022_106082 crossref_primary_10_1016_j_jss_2021_09_042 crossref_primary_10_3390_diagnostics11040668 crossref_primary_10_1016_j_colsurfb_2021_112107 crossref_primary_10_1186_s12859_020_3358_4 crossref_primary_10_1111_jrh_12350 crossref_primary_10_18596_jotcsa_1190202 crossref_primary_10_3390_ijms20235822 crossref_primary_10_1016_j_ygyno_2020_04_683 crossref_primary_10_1016_j_intimp_2021_107807 crossref_primary_10_1093_nop_npz029 crossref_primary_10_3390_antibiotics8030106 crossref_primary_10_1148_radiol_2019190647 crossref_primary_10_1007_s12094_019_02270_0 crossref_primary_10_1016_j_cgh_2019_04_043 crossref_primary_10_3390_cells11071219 crossref_primary_10_3390_cancers14051117 crossref_primary_10_1016_j_yexcr_2021_112506 crossref_primary_10_1016_j_tchem_2025_100132 crossref_primary_10_1016_j_bmc_2022_116894 crossref_primary_10_1016_j_tranon_2024_102076 crossref_primary_10_3390_cancers14236009 crossref_primary_10_1016_j_suronc_2018_05_033 crossref_primary_10_3390_ijms22179260 crossref_primary_10_1016_j_humpath_2019_09_007 crossref_primary_10_1111_jgh_15475 crossref_primary_10_3390_cancers14194912 crossref_primary_10_3389_fonc_2023_1213045 crossref_primary_10_3390_cells11142207 crossref_primary_10_1007_s00262_025_03965_w crossref_primary_10_1210_clinem_dgaa656 crossref_primary_10_1002_cam4_6038 crossref_primary_10_1371_journal_pone_0218645 crossref_primary_10_17656_jsmc_10326 crossref_primary_10_1016_j_ejrad_2019_108656 crossref_primary_10_1038_s41419_019_1645_7 crossref_primary_10_3390_molecules27217358 crossref_primary_10_1007_s10552_022_01628_0 crossref_primary_10_1136_bcr_2021_245828 crossref_primary_10_1007_s40291_021_00539_1 crossref_primary_10_1177_1078155219865008 crossref_primary_10_1016_j_chest_2023_03_016 crossref_primary_10_1186_s12885_020_07507_8 crossref_primary_10_1134_S1070428019080232 crossref_primary_10_1148_radiol_2019181931 crossref_primary_10_1016_j_biocel_2022_106358 crossref_primary_10_1080_21655979_2021_2014616 crossref_primary_10_1007_s11912_018_0742_6 crossref_primary_10_1155_2019_1569049 crossref_primary_10_1016_j_dld_2022_01_126 crossref_primary_10_1053_j_ro_2020_07_005 crossref_primary_10_1302_0301_620X_101B2_BJJ_2018_0784_R1 crossref_primary_10_1007_s10552_019_01237_4 crossref_primary_10_1158_1940_6207_CAPR_18_0341 crossref_primary_10_1001_jamainternmed_2019_4666 crossref_primary_10_1016_j_banm_2023_06_014 crossref_primary_10_1016_j_jacr_2020_06_015 crossref_primary_10_1080_01443615_2019_1621808 crossref_primary_10_1016_j_critrevonc_2019_01_010 crossref_primary_10_1016_j_lungcan_2020_05_002 crossref_primary_10_1016_j_trac_2020_116066 crossref_primary_10_1001_jamanetworkopen_2021_47343 crossref_primary_10_1016_j_cllc_2018_12_003 crossref_primary_10_1007_s11010_022_04458_5 crossref_primary_10_1016_j_oto_2021_100894 crossref_primary_10_1177_1557988320927241 crossref_primary_10_1007_s10552_019_01180_4 crossref_primary_10_1080_01635581_2018_1506489 crossref_primary_10_7759_cureus_37903 crossref_primary_10_1016_j_gore_2025_101717 crossref_primary_10_1038_s41392_019_0104_3 crossref_primary_10_1371_journal_pone_0218621 crossref_primary_10_1158_0008_5472_CAN_19_0244 crossref_primary_10_1177_10732748211056692 crossref_primary_10_1001_jamanetworkopen_2022_12246 crossref_primary_10_1093_nop_npz059 crossref_primary_10_3390_ijms26094188 crossref_primary_10_1016_j_eururo_2021_10_031 crossref_primary_10_1089_jpm_2018_0591 crossref_primary_10_1097_COC_0000000000000549 crossref_primary_10_1007_s11427_018_9461_5 crossref_primary_10_1038_s41389_019_0145_z crossref_primary_10_1186_s12885_021_08950_x crossref_primary_10_1016_j_ctarc_2021_100426 crossref_primary_10_1038_s41598_022_06934_w crossref_primary_10_1155_2020_4865738 crossref_primary_10_1186_s12957_019_1588_6 crossref_primary_10_1177_0033354921999173 crossref_primary_10_1053_j_ajkd_2019_01_037 crossref_primary_10_1186_s12885_020_6710_1 crossref_primary_10_3390_cancers14143390 crossref_primary_10_1093_neuonc_noab199 crossref_primary_10_1111_ijcp_14658 crossref_primary_10_1001_jamanetworkopen_2020_34045 crossref_primary_10_1016_j_oooo_2021_02_018 crossref_primary_10_1039_D3NR01175E crossref_primary_10_1111_omi_12332 crossref_primary_10_1186_s13638_019_1534_x |
| Cites_doi | 10.1001/jamainternmed.2016.6530 10.1001/jama.295.18.2164 10.1002/cncr.23044 10.2217/fon.09.161 10.1002/cncr.27514 10.1056/NEJMp1604412 10.1186/bcr1672 10.1177/0962280206070621 10.1002/cncr.20288 10.1002/cncr.28509 10.1353/dem.2008.0004 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z 10.1016/j.annepidem.2014.11.008 10.1093/jnci/djv048 10.7326/M17-1363 10.1016/j.amepre.2015.10.010 10.1093/jnci/djn389 10.2105/AJPH.2013.301716 10.1097/MLR.0000000000000450 10.1111/j.1365-2796.2006.01677.x 10.1093/jnci/djr077 10.3322/caac.21395 10.3322/caac.21440 10.1093/jnci/djs491 10.1007/978-1-4757-3656-4 10.1002/cncr.10593 10.1016/j.jaad.2011.04.032 10.1093/jnci/93.11.824 10.1093/jnci/91.8.675 10.1002/cncr.23724 10.1001/jama.2015.14905 10.1002/sim.3733 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I 10.1016/S0090-4295(97)00506-2 10.1001/jamainternmed.2015.2398 10.1001/jama.2017.2719 10.1093/jncimonographs/lgu018 10.1093/jnci/djg040 10.1093/jnci/djx030 10.1001/jamaoncol.2016.2667 10.1093/jnci/dji289 10.1093/jnci/94.20.1537 10.1002/cncr.29936 10.1002/cncr.24760 10.1200/JCO.2011.36.4596 10.1001/jama.2017.19130 10.1002/cncr.22193 10.1056/NEJMsr070105 |
| ContentType | Journal Article |
| Copyright | 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. 2018 American Cancer Society |
| Copyright_xml | – notice: 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. – notice: 2018 American Cancer Society |
| DBID | 24P AAYXX CITATION NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| DOI | 10.1002/cncr.31551 |
| DatabaseName | Wiley Online Library Open Access CrossRef PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Statistics |
| DocumentTitleAlternate | Annual Report National Cancer Statistics |
| EISSN | 1097-0142 |
| EndPage | 2800 |
| ExternalDocumentID | PMC6033186 29786848 10_1002_cncr_31551 CNCR31551 |
| Genre | article Research Support, U.S. Gov't, P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: North American Association of Central Cancer Registries – fundername: Centers for Disease Control and Prevention – fundername: American Cancer Society – fundername: National Cancer Institute |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ .Y3 31~ 3O- AAMMB AAQOH AAYXX AEFGJ AEYWJ AFFNX AGHNM AGNAY AGXDD AGYGG AI. AIDQK AIDYY C1A CITATION HF~ H~9 J5H N4W NEJ O8X OHT RSU VH1 WHG Y6R YQJ ZXP NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM |
| ID | FETCH-LOGICAL-c5141-814c3a093eb3f6fec8f4ec8f7136aef3da0825d04182fda041430f18cc55107d3 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 321 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000435440900019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Tue Sep 30 16:35:55 EDT 2025 Sun Sep 28 11:57:39 EDT 2025 Sat Nov 29 14:56:15 EST 2025 Wed Feb 19 02:35:05 EST 2025 Sat Nov 29 07:20:02 EST 2025 Tue Nov 18 22:12:33 EST 2025 Wed Jan 22 16:23:56 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Keywords | North American Association of Central Cancer Registries (NAACCR) Surveillance survival mortality National Program of Cancer Registries (NPCR) and End Results (SEER) cancer Annual Report to the Nation Epidemiology incidence trends National Vital Statistics System (NVSS) |
| Language | English |
| License | Attribution-NonCommercial 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5141-814c3a093eb3f6fec8f4ec8f7136aef3da0825d04182fda041430f18cc55107d3 |
| Notes | See companion article on pages 2801‐14, this issue. This article has been contributed to by US Government employees, and their work is in the public domain in the United States. The findings and conclusions in this article are those of the authors and do not necessarily represent the official positions of the author's agencies (the Centers for Disease Control and Prevention, the National Cancer Institute, the American Cancer Society, or the North American Association of Central Cancer Registries). We gratefully acknowledge the contributions of the state and regional cancer registry staff for their work in collecting the data used in this report. In addition, we thank Daniel Miller, Joe Zou, and Steve Scoppa of Information Management Services, Inc., for assistance in compiling the data used in this report. We thank Alyssa Wang, MPH, for assistance with preparation of the graphics and Trish Murphy, MS, for editorial assistance. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-5881-8313 0000-0002-0000-4111 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.31551 |
| PMID | 29786848 |
| PQID | 2056433302 |
| PQPubID | 2045183 |
| PageCount | 16 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6033186 proquest_miscellaneous_2042751581 proquest_journals_2056433302 pubmed_primary_29786848 crossref_primary_10_1002_cncr_31551 crossref_citationtrail_10_1002_cncr_31551 wiley_primary_10_1002_cncr_31551_CNCR31551 |
| PublicationCentury | 2000 |
| PublicationDate | July 1, 2018 |
| PublicationDateYYYYMMDD | 2018-07-01 |
| PublicationDate_xml | – month: 07 year: 2018 text: July 1, 2018 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta – name: Hoboken |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2018 |
| Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
| References | 2017; 317 2001; 93 2002; 94 2017; 44 2000; 88 2006; 295 1998; 82 2015; 107 2008; 100 2003; 95 2000; 19 2000 2010; 116 2015; 175 2007; 9 2011; 65 2008; 113 1998; 51 2017; 167 1999; 91 2014; 120 2011; 29 2010; 6 2004; 101 2013; 105 2006; 15 2017; 67 2016; 54 2016; 122 2016; 50 2014; 2014 2002 2001; 66 2003; 135 2009; 28 2018; 68 2007; 356 2017; 109 2011; 103 2015; 25 2016; 2 2015; 314 2007; 110 2005; 97 2016; 375 2008; 45 2017 2016; 176 2016 2018; 319 2015 2006; 260 2014 2006; 107 2012; 118 2014; 104 2016; 172 Wingo PA (e_1_2_8_2_1) 1998; 82 Howlader N (e_1_2_8_23_1) 2016 e_1_2_8_24_1 e_1_2_8_47_1 Surveillance, Epidemiology, and End Results (SEER) Program (e_1_2_8_30_1) 2015 Surveillance Research Program, National Cancer Institute (e_1_2_8_35_1) 2017 e_1_2_8_26_1 e_1_2_8_49_1 e_1_2_8_3_1 e_1_2_8_5_1 National Center for Health Statistics (e_1_2_8_25_1) 2017 e_1_2_8_7_1 e_1_2_8_9_1 Jemal A (e_1_2_8_51_1) 2011; 65 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_66_1 e_1_2_8_45_1 e_1_2_8_64_1 Centers for Medicare and Medicaid Services (CMS), HHS (e_1_2_8_62_1) 2001; 66 e_1_2_8_41_1 e_1_2_8_60_1 e_1_2_8_17_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_59_1 e_1_2_8_15_1 e_1_2_8_57_1 e_1_2_8_55_1 e_1_2_8_11_1 Altekruse SF (e_1_2_8_29_1) 2017; 44 e_1_2_8_34_1 National Vital Statistics System (e_1_2_8_31_1) 2016 National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health (e_1_2_8_53_1) 2014 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 Arias E (e_1_2_8_28_1) 2016; 172 World Health Organization (e_1_2_8_22_1) 2000 e_1_2_8_4_1 Surveillance Research Program (e_1_2_8_38_1) e_1_2_8_6_1 e_1_2_8_8_1 e_1_2_8_21_1 e_1_2_8_44_1 e_1_2_8_65_1 American Cancer Society (e_1_2_8_42_1) 2017 e_1_2_8_63_1 e_1_2_8_61_1 e_1_2_8_18_1 e_1_2_8_39_1 Ingram DD (e_1_2_8_32_1) 2003; 135 e_1_2_8_14_1 e_1_2_8_16_1 Surveillance Research Program (e_1_2_8_40_1) 2017 e_1_2_8_58_1 Surveillance Research Program (e_1_2_8_37_1) 2017 e_1_2_8_10_1 e_1_2_8_56_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_54_1 e_1_2_8_52_1 e_1_2_8_50_1 |
| References_xml | – volume: 15 start-page: 547 year: 2006 end-page: 569 article-title: Efficient interval estimation for age‐adjusted cancer rates publication-title: Stat Methods Med Res – volume: 175 start-page: 1574 year: 2015 end-page: 1576 article-title: Deaths due to cigarette smoking for 12 smoking‐related cancers in the United States publication-title: JAMA Intern Med – volume: 109 year: 2017 article-title: Annual report to the nation on the status of cancer, 1975‐2014, featuring survival publication-title: J Natl Cancer Inst – volume: 167 start-page: 714 year: 2017 end-page: 724 article-title: Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014 publication-title: Ann Intern Med – volume: 94 start-page: 2766 year: 2002 end-page: 2792 article-title: Annual report to the nation on the status of cancer, 1973‐1999, featuring implications of age and aging on US cancer burden publication-title: Cancer – volume: 122 start-page: 1312 year: 2016 end-page: 1337 article-title: Annual report to the nation on the status of cancer, 1975‐2012, featuring the increasing incidence of liver cancer publication-title: Cancer – volume: 44 start-page: 30 year: 2017 end-page: 33 article-title: Comparing cancer registry abstracted and self‐reported data on race and ethnicity publication-title: J Registry Manag – volume: 107 start-page: 1711 year: 2006 end-page: 1742 article-title: Annual report to the nation on the status of cancer, 1975‐2003, featuring cancer among US Hispanic/Latino populations publication-title: Cancer – volume: 2014 start-page: 198 year: 2014 end-page: 209 article-title: Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population‐based cancer survival studies publication-title: J Natl Cancer Inst Monogr – volume: 6 start-page: 185 year: 2010 end-page: 188 article-title: Increasing incidence of thyroid cancer: is diagnostic scrutiny the sole explanation? publication-title: Future Oncol. – volume: 104 start-page: 286 issue: suppl 3 year: 2014 end-page: 294 article-title: Methods for improving the quality and completeness of mortality data for American Indians and Alaska Natives publication-title: Am J Public Health – volume: 9 start-page: R28 year: 2007 article-title: Recent trends in breast cancer incidence rates by age and tumor characteristics among US women [serial online] publication-title: Breast Cancer Res – volume: 54 start-page: 133 year: 2016 end-page: 139 article-title: Trends in black‐white disparities in breast and colorectal cancer screening rates in a changing screening environment: the Peters‐Belson approach using United States National Health Interview Surveys 2000‐2010 publication-title: Med Care – year: 2014 – volume: 25 start-page: 179 year: 2015 end-page: 182.e171 article-title: What proportion of cancer deaths in the contemporary United States is attributable to cigarette smoking? publication-title: Ann Epidemiol – volume: 88 start-page: 2398 year: 2000 end-page: 2424 article-title: The annual report to the nation on the status of cancer, 1973‐1997, with a special section on colorectal cancer publication-title: Cancer – volume: 375 start-page: 614 year: 2016 end-page: 617 article-title: Worldwide thyroid‐cancer epidemic? The increasing impact of overdiagnosis publication-title: N Engl J Med – volume: 82 start-page: 1197 year: 1998 end-page: 1207 article-title: Cancer incidence and mortality, 1973‐1995: a report card for the United States publication-title: Cancer – volume: 94 start-page: 1537 year: 2002 end-page: 1545 article-title: Impact of reporting delay and reporting error on cancer incidence rates and trends publication-title: J Natl Cancer Inst – volume: 314 start-page: 2054 year: 2015 end-page: 2061 article-title: Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations publication-title: JAMA – volume: 103 start-page: 714 year: 2011 end-page: 736 article-title: Annual report to the nation on the status of cancer, 1975‐2007, featuring tumors of the brain and other nervous system publication-title: J Natl Cancer Inst – volume: 105 start-page: 175 year: 2013 end-page: 201 article-title: Annual report to the nation on the status of cancer, 1975‐2009, featuring the burden and trends in human papillomavirus (HPV)‐associated cancers and HPV vaccination coverage levels publication-title: J Natl Cancer Inst – volume: 50 start-page: e123 year: 2016 end-page: e131 article-title: Mammography use and physician recommendation after the 2009 US Preventive Services Task Force breast cancer screening recommendations publication-title: Am J Prev Med – volume: 68 start-page: 31 year: 2018 end-page: 54 article-title: Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States publication-title: CA Cancer J Clin – volume: 45 start-page: 143 year: 2008 end-page: 155 article-title: A practical approach to using multiple‐race response data: a bridging method for public‐use microdata publication-title: Demography – volume: 100 start-page: 1672 year: 2008 end-page: 1694 article-title: Annual report to the nation on the status of cancer, 1975‐2005, featuring trends in lung cancer, tobacco use, and tobacco control publication-title: J Natl Cancer Inst – volume: 107 start-page: djv048 year: 2015 article-title: Annual report to the nation on the status of cancer, 1975‐2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state [serial online] publication-title: J Natl Cancer Inst – volume: 118 start-page: 2338 year: 2012 end-page: 2366 article-title: Annual report to the nation on the status of cancer, 1975‐2008, featuring cancers associated with excess weight and lack of sufficient physical activity publication-title: Cancer – volume: 51 start-page: 203 year: 1998 end-page: 205 article-title: Increased incidence of serendipitously discovered renal cell carcinoma publication-title: Urology – year: 2015 – volume: 19 start-page: 335 year: 2000 end-page: 351 article-title: Permutation tests for joinpoint regression with applications to cancer rates publication-title: Stat Med – volume: 97 start-page: 1407 year: 2005 end-page: 1427 article-title: Annual report to the nation on the status of cancer, 1975‐2002, featuring population‐based trends in cancer treatment publication-title: J Natl Cancer Inst – volume: 91 start-page: 675 year: 1999 end-page: 690 article-title: Annual report to the nation on the status of cancer, 1973‐1996, with a special section on lung cancer and tobacco smoking publication-title: J Natl Cancer Inst – volume: 317 start-page: 1338 year: 2017 end-page: 1348 article-title: Trends in thyroid cancer incidence and mortality in the United States, 1974‐2013 publication-title: JAMA – volume: 95 start-page: 1276 year: 2003 end-page: 1299 article-title: Annual report to the nation on the status of cancer, 1975‐2000, featuring the uses of surveillance data for cancer prevention and control publication-title: J Natl Cancer Inst – volume: 295 start-page: 2164 year: 2006 end-page: 2167 article-title: Increasing incidence of thyroid cancer in the United States, 1973‐2002 publication-title: JAMA – year: 2000 – volume: 113 start-page: 1120 issue: suppl 5 year: 2008 end-page: 1130 article-title: Methods for improving cancer surveillance data in American Indian and Alaska Native populations publication-title: Cancer – volume: 356 start-page: 1670 year: 2007 end-page: 1674 article-title: The decrease in breast‐cancer incidence in 2003 in the United States publication-title: N Engl J Med – volume: 260 start-page: 103 year: 2006 end-page: 117 article-title: Interpreting trends in cancer patient survival publication-title: J Intern Med – year: 2016 – volume: 172 start-page: 1 year: 2016 end-page: 21 article-title: The validity of race and Hispanic‐origin reporting on death certificates in the United States: an update. [DHHS Publication No. 2016‐1372] publication-title: Vital Health Stat 2. – volume: 176 start-page: 1792 year: 2016 end-page: 1798 article-title: State‐level cancer mortality attributable to cigarette smoking in the United States publication-title: JAMA Intern Med – volume: 101 start-page: 3 year: 2004 end-page: 27 article-title: Annual report to the nation on the status of cancer, 1975‐2001, with a special feature regarding survival publication-title: Cancer – volume: 28 start-page: 3670 year: 2009 end-page: 3682 article-title: Estimating average annual per cent change in trend analysis publication-title: Stat Med – volume: 120 start-page: 1290 year: 2014 end-page: 1314 article-title: Annual report to the nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer publication-title: Cancer – volume: 135 start-page: 1 year: 2003 end-page: 55 article-title: United States Census 2000 population with bridged race categories publication-title: Vital Health Stat 2 – volume: 116 start-page: 544 year: 2010 end-page: 573 article-title: Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates publication-title: Cancer – volume: 319 start-page: 154 year: 2018 end-page: 164 article-title: Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000‐2012 publication-title: JAMA – year: 2002 – volume: 67 start-page: 177 year: 2017 end-page: 193 article-title: Colorectal cancer statistics, 2017 publication-title: CA Cancer J Clin – volume: 66 start-page: 55246 year: 2001 end-page: 55503 article-title: Medicare program; revisions to payment policies and 5‐year review of and adjustments to the relative value units under the physician fee schedule for calendar year 2002: final rule with comment period publication-title: Fed Regist. – volume: 29 start-page: 4294 year: 2011 end-page: 4301 article-title: Human papillomavirus and rising oropharyngeal cancer incidence in the United States publication-title: J Clin Oncol – volume: 110 start-page: 2119 year: 2007 end-page: 2152 article-title: Annual report to the nation on the status of cancer, 1975‐2004, featuring cancer in American Indians and Alaska Natives publication-title: Cancer – volume: 93 start-page: 824 year: 2001 end-page: 842 article-title: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends publication-title: J Natl Cancer Inst – year: 2017 – volume: 65 start-page: S17 issue: 5 suppl 1 year: 2011 end-page: S25 article-title: Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992‐2006 publication-title: J Am Acad Dermatol – volume: 2 start-page: 1657 year: 2016 end-page: 1660 article-title: Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening publication-title: JAMA Oncol – volume: 44 start-page: 30 year: 2017 ident: e_1_2_8_29_1 article-title: Comparing cancer registry abstracted and self‐reported data on race and ethnicity publication-title: J Registry Manag – ident: e_1_2_8_55_1 doi: 10.1001/jamainternmed.2016.6530 – volume-title: Bridged‐Race Population Estimates—Data Files and Documentation year: 2016 ident: e_1_2_8_31_1 – ident: e_1_2_8_43_1 doi: 10.1001/jama.295.18.2164 – ident: e_1_2_8_11_1 doi: 10.1002/cncr.23044 – ident: e_1_2_8_46_1 doi: 10.2217/fon.09.161 – ident: e_1_2_8_15_1 doi: 10.1002/cncr.27514 – ident: e_1_2_8_44_1 doi: 10.1056/NEJMp1604412 – ident: e_1_2_8_49_1 doi: 10.1186/bcr1672 – ident: e_1_2_8_36_1 doi: 10.1177/0962280206070621 – ident: e_1_2_8_8_1 doi: 10.1002/cncr.20288 – ident: e_1_2_8_17_1 doi: 10.1002/cncr.28509 – volume: 135 start-page: 1 year: 2003 ident: e_1_2_8_32_1 article-title: United States Census 2000 population with bridged race categories publication-title: Vital Health Stat 2 – volume-title: Cancer Facts & Figures 2017 year: 2017 ident: e_1_2_8_42_1 – ident: e_1_2_8_66_1 doi: 10.1353/dem.2008.0004 – volume-title: The Health Consequences of Smoking: 50 Years of Progress—A Report of the Surgeon General year: 2014 ident: e_1_2_8_53_1 – volume: 82 start-page: 1197 year: 1998 ident: e_1_2_8_2_1 article-title: Cancer incidence and mortality, 1973‐1995: a report card for the United States publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0 – ident: e_1_2_8_39_1 doi: 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z – volume-title: International Classification of Diseases for Oncology year: 2000 ident: e_1_2_8_22_1 – ident: e_1_2_8_54_1 doi: 10.1016/j.annepidem.2014.11.008 – ident: e_1_2_8_18_1 doi: 10.1093/jnci/djv048 – ident: e_1_2_8_65_1 doi: 10.7326/M17-1363 – volume-title: SEER Cancer Statistics Review, 1975‐2014 year: 2016 ident: e_1_2_8_23_1 – ident: e_1_2_8_50_1 doi: 10.1016/j.amepre.2015.10.010 – ident: e_1_2_8_12_1 doi: 10.1093/jnci/djn389 – ident: e_1_2_8_26_1 doi: 10.2105/AJPH.2013.301716 – ident: e_1_2_8_60_1 doi: 10.1097/MLR.0000000000000450 – ident: e_1_2_8_52_1 doi: 10.1111/j.1365-2796.2006.01677.x – volume: 172 start-page: 1 year: 2016 ident: e_1_2_8_28_1 article-title: The validity of race and Hispanic‐origin reporting on death certificates in the United States: an update. [DHHS Publication No. 2016‐1372] publication-title: Vital Health Stat 2. – ident: e_1_2_8_14_1 doi: 10.1093/jnci/djr077 – ident: e_1_2_8_61_1 doi: 10.3322/caac.21395 – ident: e_1_2_8_63_1 doi: 10.3322/caac.21440 – volume-title: Mortality Data, 2015 year: 2017 ident: e_1_2_8_25_1 – ident: e_1_2_8_16_1 doi: 10.1093/jnci/djs491 – volume-title: SEER*Stat Software year: 2017 ident: e_1_2_8_35_1 – ident: e_1_2_8_33_1 doi: 10.1007/978-1-4757-3656-4 – ident: e_1_2_8_6_1 doi: 10.1002/cncr.10593 – volume: 65 start-page: S17 issue: 5 year: 2011 ident: e_1_2_8_51_1 article-title: Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992‐2006 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2011.04.032 – ident: e_1_2_8_5_1 doi: 10.1093/jnci/93.11.824 – ident: e_1_2_8_3_1 doi: 10.1093/jnci/91.8.675 – ident: e_1_2_8_27_1 doi: 10.1002/cncr.23724 – ident: e_1_2_8_58_1 doi: 10.1001/jama.2015.14905 – volume-title: Average Annual Percent Change (AAPC) and Confidence Interval year: 2017 ident: e_1_2_8_40_1 – volume-title: Joinpoint Regression Program ident: e_1_2_8_38_1 – ident: e_1_2_8_41_1 doi: 10.1002/sim.3733 – ident: e_1_2_8_4_1 doi: 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I – ident: e_1_2_8_21_1 – ident: e_1_2_8_47_1 doi: 10.1016/S0090-4295(97)00506-2 – volume-title: Population Estimates Used in NCI's SEER*Stat Software year: 2015 ident: e_1_2_8_30_1 – ident: e_1_2_8_56_1 doi: 10.1001/jamainternmed.2015.2398 – ident: e_1_2_8_45_1 doi: 10.1001/jama.2017.2719 – ident: e_1_2_8_34_1 doi: 10.1093/jncimonographs/lgu018 – ident: e_1_2_8_7_1 doi: 10.1093/jnci/djg040 – ident: e_1_2_8_20_1 doi: 10.1093/jnci/djx030 – volume-title: Cancer Incidence Rates Adjusted for Reporting Delay year: 2017 ident: e_1_2_8_37_1 – ident: e_1_2_8_59_1 doi: 10.1001/jamaoncol.2016.2667 – ident: e_1_2_8_9_1 doi: 10.1093/jnci/dji289 – ident: e_1_2_8_24_1 doi: 10.1093/jnci/94.20.1537 – ident: e_1_2_8_19_1 doi: 10.1002/cncr.29936 – ident: e_1_2_8_13_1 doi: 10.1002/cncr.24760 – ident: e_1_2_8_64_1 doi: 10.1200/JCO.2011.36.4596 – volume: 66 start-page: 55246 year: 2001 ident: e_1_2_8_62_1 article-title: Medicare program; revisions to payment policies and 5‐year review of and adjustments to the relative value units under the physician fee schedule for calendar year 2002: final rule with comment period publication-title: Fed Regist. – ident: e_1_2_8_57_1 doi: 10.1001/jama.2017.19130 – ident: e_1_2_8_10_1 doi: 10.1002/cncr.22193 – ident: e_1_2_8_48_1 doi: 10.1056/NEJMsr070105 |
| SSID | ssj0007253 |
| Score | 2.7074873 |
| Snippet | BACKGROUND
The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American... The National Cancer Institute, the Centers for Disease Control and Prevention, the American Cancer Society, and the North American Association of Central... The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American... BACKGROUNDThe American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2785 |
| SubjectTerms | and End Results (SEER) Annual Report to the Nation Brain Breast cancer Bronchus Cancer Children Colon Colon cancer Colorectal cancer Colorectal carcinoma Death Disease control Epidemiology Ethnicity Health risk assessment Incidence Liver Lung cancer Melanoma Men Minority & ethnic groups Mortality National Program of Cancer Registries (NPCR) National Vital Statistics System (NVSS) Nervous system North American Association of Central Cancer Registries (NAACCR) Oncology Oral cavity Original Pancreas Pharynx Prostate Race Rectum Skin Statistical analysis Statistics Surveillance Survival Trends Uterus Vital statistics Women |
| Title | Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.31551 https://www.ncbi.nlm.nih.gov/pubmed/29786848 https://www.proquest.com/docview/2056433302 https://www.proquest.com/docview/2042751581 https://pubmed.ncbi.nlm.nih.gov/PMC6033186 |
| Volume | 124 |
| WOSCitedRecordID | wos000435440900019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1097-0142 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0142 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swED5CU8Ze1nXd2rRZ0WhfOmZqS4olj72MbGGFNoSw0LwZWZZooTglafb39yQ5bkPKYAyMsNDZlqU76Tv9-ARwajXN0EsQkRaZibhOi0hlrIx4SgsrWKJiXvrDJsRwKKfTbNSCb6u9MIEfohlwc5bh22tn4KpYnD-RhupKz9Hj7Ln90-0kYdId3ED5qGmHBa05KGMZ9TibNuSk9Pzp2fXuaANjbi6VfA5hfR802Pm_3L-FNzX2JN-DsuxCy1Tv4NVVPbu-B9eBbJ8EUE4eZgTRIQnM2QQvF3PgdLkgM0v6Tl_mX8g9Kh-5-FrL4ePaJxC3VSmwQL-HyeDn7_6vqD54IdKInxI3LKiZijOGnrZNrdHSchegQ5sqY1mpnGNZxhydE4sRjqArtonUGv8nFiX7AFvVrDIHQKQyhWXCalkkXBSqQPzDWKFMxjJECrIDZ6vyz3XNSu4Ox7jLA58yzV1J5b6kOnDSyN4HLo4Xpbqrasxre1zkFHEeZ4zFtAOfmmS0JDc9oiozWzoZTgXCO4mv2A-13nwGFVqmkmN2xZo-NAKOpXs9pbq98Wzdacyw3Uw78Nnrw19ynveH_bG_O_wX4SN4jShOhjXEXdh6mC_NR9jWf7CS58feJjAUU3kM7R_jweQSY9cXw0ddgxK6 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swED5GVtq9bN3abt7aTWN7aamJY6mWvLcRVhqWmDI6kjcjyxIbDCekzf7-3Umuu9BSKAVjLHSyZelO-k4_PgF8dibN0UuQsZG5jYXJqljnvI5FllZO8oFORO0Pm5BFoWaz_Lxdm0N7YQI_RDfgRpbh22sycBqQ7t-whprGLNHlPKEN1E8FIg06uWE6KrqGWKYtCWWi4hPBZx07adq_SbveH90CmbfXSv6PYX0ndPrikdnfhuct-mRfg7q8hCe2eQWbk3Z-fQemgW6fBVjOruYM8SEL3NkMLwoRPF1dsrljQ9KY5TFboPqx0ZdWDpMbH8Fos1Lggd6Fn6ffLoZncXv0QmwQQQ1oYNBwneQcfW2XOWuUE3RDlzbT1vFak2tZJwLdE4cBgbArcQNlDP5PImu-B71m3tg3wJS2lePSGVUNhKx0hQiI80rbnOeIFVQEh9cVUJqWl5yOx_hTBkbltKSSKn1JRfCpk10ENo47pfav67FsLfKyTBHpCc55kkbwsYtGW6IJEt3Y-YpkRCoR4Cl8xetQ7d1nUKVVpgRmV64pRCdAPN3rMc3vX56vO0s4tpxZBEdeIe7JeTkshj_809uHCH-ArbOLybgcj4rv7-AZYjoVVhTvQ-9qubIHsGH-YoUv33sD-QfY9xN7 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB9kFfFFzzs_1vM04r0oFrtNbNJ7O1YX5XQRUdy3kqYJHhzdZXX9-51pYnVRDkQopSHTNh8zyW_y8QvAT2eSDL0EGRmZ2UiYtIh0xstIpEnhJO_oWJT1YROy31eDQXYZ1ubQXhjPD9EMuJFl1O01Gbgdle7whTXUVGaMLucRbaCeFXSKTAtmj696N-dNUyyTQEMZq-hI8EHDT5ocvrw93SO9gZlvV0u-RrF1N9Rb-mQGvsBiwJ_st1eYZZix1VeYvwgz7N_g1hPuMw_M2cOQIUJknj2b4UUhAqiTezZ0rEs6Mz5gI1RAdvYryOHrpo5gtF3JM0GvwE3v5Lp7GoXDFyKDGKpDQ4OG6zjj6G271FmjnKAbOrWpto6XmpzLMhbooDgMCAResesoYzA_sSz5KrSqYWXXgSltC8elM6roCFnoAjEQ54W2Gc8QLag27D1XQG4CMzkdkPEv95zKSU4lldcl1YbdRnbk-Tjeldp8rsc82OR9niDWE5zzOGnDThON1kRTJLqywwnJiEQixFP4iTVf7c1vUKlVqgQmV04pRCNATN3TMdXfu5qxO405tp1pG_ZrhfhPyvNuv3tVP218RHgb5i-Pe_n5Wf_Pd1hAUKf8kuJNaD2MJ_YHzJlHrO_xVrCQJ6MNFCQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Annual+Report+to+the+Nation+on+the+Status+of+Cancer%2C+part+I%3A+National+cancer+statistics&rft.jtitle=Cancer&rft.au=Cronin%2C+Kathleen+A&rft.au=Lake%2C+Andrew+J&rft.au=Scott%2C+Susan&rft.au=Sherman%2C+Recinda+L&rft.date=2018-07-01&rft.eissn=1097-0142&rft.volume=124&rft.issue=13&rft.spage=2785&rft_id=info:doi/10.1002%2Fcncr.31551&rft_id=info%3Apmid%2F29786848&rft.externalDocID=29786848 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |